Oncology Briefings™: Highlights from San Antonio - Clinical Updates in Breast Cancer Care

Release Date: February 28, 2020
Expiration Date: February 28, 2021
Media: Internet - based

Activity Overview

This article is an extension of the annual School of Breast Oncology^® Live Video Webcast: Clinical Updates from San Antonio program that featured leading experts in the field of breast cancer who provided a comprehensive overview of noteworthy data presented at the international society meeting held in San Antonio in December of 2019. The article provides an additional forum for clinicians to keep pace with rapidly emerging data and advancing treatment paradigms in breast cancer.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Athenex; Daiichi Sankyo, Inc.; Foundation Medicine, Inc.; Genomic Health, Inc.; Merck & Co., Inc.; and Seattle Genetics, Inc.

Target Audience

This activity is directed toward medical oncologists who treat patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Discuss the study design and primary endpoints of recently reported and ongoing clinical trials evaluating novel strategies for the management of breast cancer
• Compare and contrast the safety and efficacy profiles of novel therapeutic strategies that impact breast cancer management
• Integrate emerging evidence into the treatment paradigm across the breast cancer disease type and stage continuum

Faculty, Staff, and Planners’ Disclosures

Faculty

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Co-Chair of the Breast Cancer Research Program
The US Oncology Network
Dallas, TX

Disclosures: Honoraria for consulting and advisory boards: AbbVie Inc, Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals, Takeda.

Tiffany A. Traina, MD
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor
Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: Astellas Pharma, AstraZeneca, Daiichi Sankyo, Eisai, Genentech/Roche, Immunomedics, Innocrin Pharma, Novartis, Pfizer. Consultant: Aduro Biotech, Advaxis, Astellas Pharma, AstraZeneca, Athenex, Bristol-Myers Squibb, Celgene, Genentech, Genomic Health, Halozyme, Innocrin Pharma, Medivation, Merck, Pfizer, Puma Biotechnology, Samsung. Speakers Bureau: Genentech/Roche.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.